MDAI vs. PDEX, NVRO, ZJYL, TLSI, ECOR, SRTS, TELA, LNSR, FONR, and GUTS
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include Pro-Dex (PDEX), Nevro (NVRO), Jin Medical International (ZJYL), TriSalus Life Sciences (TLSI), electroCore (ECOR), Sensus Healthcare (SRTS), TELA Bio (TELA), LENSAR (LNSR), FONAR (FONR), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry.
Spectral AI vs.
Spectral AI (NASDAQ:MDAI) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
Pro-Dex received 149 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 61.85% of users gave Pro-Dex an outperform vote.
In the previous week, Spectral AI had 2 more articles in the media than Pro-Dex. MarketBeat recorded 3 mentions for Spectral AI and 1 mentions for Pro-Dex. Spectral AI's average media sentiment score of 0.24 beat Pro-Dex's score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.
Spectral AI presently has a consensus price target of $4.50, suggesting a potential upside of 121.67%. Pro-Dex has a consensus price target of $52.00, suggesting a potential upside of 8.04%. Given Spectral AI's stronger consensus rating and higher possible upside, equities research analysts clearly believe Spectral AI is more favorable than Pro-Dex.
Pro-Dex has a net margin of 9.17% compared to Spectral AI's net margin of -40.78%. Pro-Dex's return on equity of 16.74% beat Spectral AI's return on equity.
Pro-Dex has higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
67.1% of Spectral AI shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 56.7% of Spectral AI shares are held by company insiders. Comparatively, 47.5% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Spectral AI has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
Summary
Spectral AI beats Pro-Dex on 10 of the 19 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Spectral AI Competitors List
Related Companies and Tools
This page (NASDAQ:MDAI) was last updated on 12/25/2024 by MarketBeat.com Staff